{"pub": "investingcom", "url": "https://investing.com/news/stock-market-news/newsbreak-carcinogen-found-in-heartburn-drug-zantac-1977587", "downloaded_at": "2019-09-13 18:55:07.299832+00:00", "title": "NewsBreak: Low Levels of Carcinogen Found in Heartburn Drug Zantac", "language": "en", "text": "NewsBreak: Low Levels of Carcinogen Found in Heartburn Drug Zantac\n\nStock Markets 4 hours ago (Sep 13, 2019 10:28AM ET)\n\n\u00a9 Reuters. Investing.com - U.S. and European health officials are investigating big-selling heartburn treatment Zantac and generics of the drug after a carcinogen was discovered in low levels, Bloomberg first reported Friday. The drug ranitidine, branded as Zantac, was found to contain levels of a probable carcinogen in testing by an online pharmacy. The same contaminant prompted a recall of blood-pressure pills last year. \"The FDA is evaluating whether the low levels of (the contaminant) NDMA in ranitidine pose a risk to patients,\" the regulator said. It added that it is not recommending patients stop taking the medication at this time. Sanofi (PA: ), the maker of Zantac, fell 0.8% in Paris trading. Its ADRs (NASDAQ: ) lost 0.3%.\n\nNewsBreak: Low Levels of Carcinogen Found in Heartburn Drug Zantac", "description": "NewsBreak: Low Levels of Carcinogen Found in Heartburn Drug Zantac", "authors": [], "top_image": "https://i-invdn-com.akamaized.net/news/LYNXNPEE7M0VV_L.jpg", "published_at": "2019-09-13"}